Skip to Main Content

Paper Details

Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
J Med Chem
2
2023
AR, AR +, AR Mutants, AR mutants, AR protein, AR+, ARD-1676, Cancer, Human, LNCaP, LNCaP cell lines, VCaP, VCaP mouse xenograft tumor, VCaP tumor, androgen, androgen receptor, cereblon, dogs, human, mice, monkeys, mouse, prostate cancer, rats, tumor
Author NameAffiliation
Bo WenDepartment of Pharmaceutical Sciences, University of Michigan ann arbor
Arul M ChinnaiyanUniversity of Michigan ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan ann arbor
Arul M ChinnaiyanRogel Cancer Center, University of Michigan ann arbor
Arul M ChinnaiyanHoward Hughes Medical Institute, University of Michigan ann arbor
Arul M ChinnaiyanUniversity of Michigan ann arbor
Arul M ChinnaiyanMichigan Center for Translational Pathology, University of Michigan ann arbor
Arul M ChinnaiyanRogel Cancer Center, University of Michigan ann arbor
Arul M ChinnaiyanHoward Hughes Medical Institute, University of Michigan ann arbor
  • 1 - 9

Datasets

Release 1.2